M
Michael L. Linenberger
Researcher at Fred Hutchinson Cancer Research Center
Publications - 72
Citations - 3322
Michael L. Linenberger is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Feline immunodeficiency virus. The author has an hindex of 25, co-authored 67 publications receiving 3143 citations. Previous affiliations of Michael L. Linenberger include University of Washington & Seattle Cancer Care Alliance.
Papers
More filters
Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.
Zbigniew M. Szczepiorkowski,Jeffrey L. Winters,Nicholas Bandarenko,Haewon C. Kim,Michael L. Linenberger,Marisa B. Marques,Ravindra Sarode,Joseph E. Schwartz,Robert Weinstein,Beth H. Shaz +9 more
TL;DR: The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions and a new concept of a fact sheet has been introduced that succinctly summarizes the evidence for the use of therapeutic apheresis.
Journal ArticleDOI
Venous thromboembolic disease
Lawrence D. Wagman,Melissa F. Baird,Charles L. Bennett,Paula L. Bockenstedt,Spero R. Cataland,John Fanikos,Patrick F. Fogarty,Samuel Z. Goldhaber,Tejpal Grover,William Haire,Hani Hassoun,Suzanne Hutchinson,Mohammad Jahanzeb,Jason T. Lee,Michael L. Linenberger,Michael Millenson,Thomas L. Ortel,Riad Salem,Judy L. Smith,Michael B. Streiff,Suresh Vedantham +20 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.
Journal ArticleDOI
Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology.
Wagman Ld,Melissa F. Baird,Charles L. Bennett,Paula L. Bockenstedt,Cataland,John Fanikos,Patrick F. Fogarty,Samuel Z. Goldhaber,Tejpal Grover,W.D. Haire,Hani Hassoun,Hutchinson S,Mohammad Jahanzeb,Jason T. Lee,Michael L. Linenberger,Michael Millenson,Thomas L. Ortel,Riad Salem,Judy L. Smith,Michael B. Streiff,Suresh Vedantham +20 more
Journal ArticleDOI
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance
TL;DR: Since 2000, when GO was approved for clinical use, treatment trials and pilot studies have revealed potential expanded applications along with additional limitations, and GO serves as an important paradigm for other immunoconjugates against internalizing tumor antigens.
Journal ArticleDOI
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
Michael L. Linenberger,Tom C. Hong,David A. Flowers,Eric L. Sievers,Ted Gooley,John M. Bennett,Mark S. Berger,Lance Leopold,Frederick R. Appelbaum,Irwin D. Bernstein +9 more
TL;DR: In this article, surface expression of P-glycoprotein (Pgp) correlated with Pgp function, as indicated by elevated dye efflux that was inhibited by cyclosporine (CSA).